Výsledky vyhledávání - "Josh Dekeyser"

Evaluation of the time-course of CYP Induction and impact on drug interaction risk assessment from the IQ Induction working group

Autor: Kelly Nulick, Niresh Hariparsad, Jane R. Kenny, Barry Jones, Donald J. Tweedie, Theunis C. Goosen, Heidi J. Einolf, Shannon Dallas, David B. Buckley, Diane Ramsden, Josh Dekeyser, George Zhang, Jairam Palamanda, Phillip D. Yates, Mike Mohutsky, Amy Siu, Simon Wong

Publikováno v: Drug Metabolism and Pharmacokinetics. 34:S40

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::7344b916e04475c548063cd5258f78ba
https://doi.org/10.1016/j.dmpk.2018.09.146

Zobrazit plný text záznamu

Recommendations for in vitro CYP3A4 mRNA data analysis for drug-drug interaction risk assessment from the IQ Induction working group

Autor: Maria Fitzgerald, Diane Ramsden, Jane R. Kenny, Josh Dekeyser, Y. Amy Siu, Donald J. Tweedie, Michael A. Mohutsky, Liangfu Chen, George Zhang, Niresh Hariparsad, Shannon Dallas, Theunis C. Goosen, David B. Buckley, Heidi J. Einolf, Robert L. Walsky, Conrad Fung

Publikováno v: Drug Metabolism and Pharmacokinetics. 34:S44

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::45a3e024730458a700e00c895f82206d
https://doi.org/10.1016/j.dmpk.2018.09.159

Zobrazit plný text záznamu

P-0199 Mechanisms Mediating The Negative Interaction Between Oxaliplatin and Epidermal Growth Factor Receptor Inhibitors in Patients With KRAS Mutant Colorectal Cancer

Autor: Robert Radinsky, Josh Dekeyser, Juan Gloria, Nicholas Potter, Daniel J. Freeman, Selam Ogbagabriel, Jiansong Xie

Publikováno v: Annals of Oncology. 23:iv87

Introduction Platinum agents are a standard of care for the treatment of many cancers. Phase 3 trials have shown that patients (pts) with mutant (MT) KRAS tumors have shorter progression-free survival and overall survival when panitumumab or cetuxima

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::0a847588b262b9d51c354f1764529739
https://doi.org/10.1016/s0923-7534(20)30124-1

Zobrazit plný text záznamu

Mechanisms mediating the negative interaction between oxaliplatin (Ox) and epidermal growth factor receptor (EGFR) inhibitors in patients (pts) with KRAS mutant (MT) colorectal cancer (CRC)

Autor: Selam Ogbagabriel, Daniel J. Freeman, Gloria Juan, Josh Dekeyser, Robert Radinsky, Nicholas Potter, Jiansong Xie

Publikováno v: Journal of Clinical Oncology. 30:3580-3580

3580 Background: Phase 3 trials have shown that pts with MT KRAS tumors have shorter progression-free survival and overall survival when an EGFR inhibitor is added to Ox-containing chemotherapy (CT) (Bokemeyer et al 2011, Douillard et al 2010). Howev

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::e876c1c02b5540bc7e6cf85ebfaa2055
https://doi.org/10.1200/jco.2012.30.15_suppl.3580

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání